What GLP-1 Medications Cost Without Insurance
Three drugs, three published price ladders, and one arithmetic trap that makes the injections cost more per year than their monthly price suggests.
- 13Fills a year on the weekly injections, not 12 — their month is 28 days
- $3,650A year of Foundayo at its highest dose, the cheapest maintenance option
- $5,840A year of Zepbound at 15 mg, refilled on time every time
- $3,250The yearly penalty for refilling Zepbound outside its 45-day window
The short version
How much do these drugs cost without insurance? Wegovy runs $149 to $399 a month depending on form and dose, Zepbound $299 to $449 on one condition, and Foundayo — the oral option approved in 2026 — $149 to $299. Paying cash is substantially cheaper than it was, because Novo Nordisk and Eli Lilly both now sell direct to patients rather than only through pharmacies and insurers.
None of these is a single number, because all three are ladders. What you pay depends on which dose you are on, and the dose you start at is not the dose you stay on. Every figure below comes from the manufacturer’s own published price list, and every annual total shows its arithmetic — including how many times a year you actually refill, which is not twelve for all of them.
The cost of Wegovy without insurance, dose by dose
Wegovy now exists in two forms, and the tablet is materially cheaper than the pen at every comparable point.
| Form and dose | Self-pay price, per month |
|---|---|
| Tablet, 1.5 mg | $149 |
| Tablet, 4 mg | $199 |
| Tablet, 9 mg and 25 mg | $299 |
| Pen, 0.25 mg and 0.5 mg — first two fills, new patients | $199 |
| Pen, 0.25 to 2.4 mg — thereafter | $349 |
| Pen HD, 7.2 mg | $399 |
One of these prices is dated rather than permanent. The 4 mg tablet was $149 until 31 August 2026 and now costs $199, a change we confirmed on Novo Nordisk’s own page. The $199 introductory rate on the two lowest pen doses is limited to a new patient’s first two fills and runs through 31 December 2026.
Zepbound cost without insurance, and the 45-day condition
Lilly sells Zepbound as single-dose vials through its own self-pay pharmacy. The headline prices are competitive with Wegovy. The condition attached to them is the most consequential piece of fine print we have found in this category.
| Vial dose | Refilled within 45 days | Refilled later |
|---|---|---|
| 2.5 mg | $299 | — |
| 5 mg | $399 | — |
| 7.5 mg | $449 | $499 |
| 10 mg | $449 | $699 |
| 12.5 mg | $449 | $699 |
| 15 mg | $449 | $699 |
To hold the $449 price you must complete each refill within 45 days of receiving the previous one. Miss that window on the top dose and the price goes to $699 — a 56% increase for being late.
The arithmetic
Across a year at 15 mg — about 13 refills, because Lilly defines a month as 28 days — refilling on time costs roughly $5,840. Refilling outside the window every time costs roughly $9,090. The medication is identical. The difference is about $3,250 in scheduling.
A 45-day window against a 28-day supply leaves about two and a half weeks of slack, which is workable but not generous. A delayed delivery, a lapsed prescription, a holiday, or simply pausing because of side effects can cost the difference. Full detail on the drug itself is on our tirzepatide page.
Foundayo, the oral option that undercuts both
Approved in 2026, orforglipron is sold as Foundayo and is the first GLP-1 for weight management that is a tablet rather than a peptide injection. Lilly sells it through the same self-pay pharmacy as Zepbound, and it is cheaper at every comparable point.
| Strength | Self-pay price, per month |
|---|---|
| 0.8 mg | $149 |
| 2.5 mg | $149 until 31 December 2026 |
| 5.5 mg | $199 until 31 December 2026 |
| 9 mg | $299 |
| 14.5 mg | $299 |
| 17.2 mg | $299 |
Two of these are dated. The 2.5 mg and 5.5 mg prices are described as temporarily reduced and run only to 31 December 2026. The two highest strengths carry the same 45-day refill condition as Zepbound, so missing the window moves them off the $299 rate.
Cheaper twice over
At maintenance it is $299 a month against Zepbound’s $449 — and Lilly defines a Foundayo month as 30 days rather than 28, so you buy about 12 a year instead of 13. Both differences run the same way. Over a year that is roughly $3,650 against $5,840, a gap of about $2,200 rather than the $1,800 the monthly prices imply.
The trade is effectiveness. On each drug’s own trials Foundayo produces less weight reduction than either injection, which our orforglipron page sets out in full. Its side-effect profile is worth reading alongside the price too, since one in ten people on the highest dose stopped taking it. Cheaper is not the same as better value, and that judgement is not a pricing question.
What a full year actually costs
Each figure below assumes a full year at that dose. A real first year includes cheaper months while titrating, so these are ceilings rather than forecasts.
The fills column is the part most cost comparisons get wrong. A “month” is whatever the manufacturer’s terms say it is: 28 days for the weekly injections, which is about 13 refills a year, and 30 days for the tablets, which is about 12. Multiplying a monthly price by twelve understates every injection on this page.
| Option | Per fill | Fills a year | A year |
|---|---|---|---|
| Foundayo, 0.8 mg | $149 | ~12 | ~$1,820 |
| Wegovy tablet, 1.5 mg | $149 | ~12 | ~$1,820 |
| Wegovy tablet, 9 or 25 mg | $299 | ~12 | ~$3,650 |
| Foundayo, 17.2 mg | $299 | ~12 | ~$3,650 |
| Wegovy pen, 2.4 mg | $349 | ~13 | ~$4,540 |
| Wegovy pen HD, 7.2 mg | $399 | ~13 | ~$5,190 |
| Zepbound 15 mg, on time | $449 | ~13 | ~$5,840 |
| Zepbound 15 mg, always late | $699 | ~13 | ~$9,090 |
Prices read from each manufacturer’s own published self-pay pages on 5 September 2026. Annual totals are the price per fill multiplied by the number of fills a year that each manufacturer’s own definition of a month produces — 365 days divided by 28 for the weekly injections, and by 30 for the tablets — then rounded. These are cash prices and assume no insurance contribution.
Buying direct against buying through a telehealth platform
This is the comparison the pricing pages do not invite you to make. Ro, the only telehealth provider we found publishing dose-tiered prices, charges $349 a month for the Wegovy pen at 1 mg and above. That is the same $349 Novo Nordisk charges for the same pen bought directly.
The difference is the membership. Ro’s runs $888 a year on annual prepay, or $1,788 month to month, billed separately from the medication. Buying the same drug at the same price directly from the manufacturer carries no membership at all.
Worth knowing
What the membership buys is the prescription, the clinical check-in, and the logistics. Those have real value. What it does not buy is a better price on the drug.
Buying direct still requires a prescription from a licensed prescriber — the manufacturer pharmacies dispense, they do not prescribe. If you already have a prescribing relationship, direct is the cheaper route. If you do not, the membership is what you are paying for. Our provider comparison sets out what each platform charges and what it discloses.
Frequently asked questions
-
How much does the Wegovy pill cost without insurance?
$149 a month at 1.5 mg, $199 at 4 mg, and $299 at 9 mg and 25 mg. The 4 mg strength was $149 until 31 August 2026. Those are Novo Nordisk’s own self-pay prices through its pharmacy.
-
Is the pill cheaper than the injection?
Yes, at every comparable point. The most expensive tablet is $299 a month; the standard pen is $349 and the high-dose pen is $399. Whether the two forms suit you equally is a clinical question rather than a pricing one.
-
Why did my Zepbound price go up?
The most likely reason is the refill window. Lilly’s $449 price on the higher doses requires each refill to be completed within 45 days of the previous delivery. Outside that window, 7.5 mg is $499 and 10 mg, 12.5 mg and 15 mg are $699.
-
How much does Wegovy cost without insurance in total?
Over a full year at a steady dose, the out-of-pocket cost of Wegovy without insurance runs from about $1,820 on the cheapest tablet to about $5,190 on the high-dose pen. The most common maintenance figure is roughly $4,540 a year for the 2.4 mg pen. Note that the pen is billed in 28-day months, so a year is about 13 fills rather than 12. A real first year costs less, because you spend the early months on lower, cheaper doses.
-
What does the Wegovy injection cost without insurance?
The Wegovy pen is $349 a month at every dose from 0.25 mg through 2.4 mg, and $399 for the 7.2 mg high-dose pen. New patients pay $199 for their first two fills of the two lowest doses, an introductory rate running through 31 December 2026.
-
Is Zepbound cheaper than Wegovy without insurance?
At maintenance, no. Zepbound is $449 a month against $349 for the standard Wegovy pen, and the Wegovy tablet is cheaper still at $299. Foundayo matches that $299 and is the cheapest of the three at maintenance. Zepbound is only cheaper at its 2.5 mg starting dose, which is not a dose anyone stays on. The gap widens sharply if a Zepbound refill falls outside the 45-day window, and widens again over a year because Zepbound is billed in 28-day months rather than 30.
-
How much does Foundayo cost without insurance?
$149 a month at the two lowest strengths and $299 at 9 mg and above, from Lilly’s own self-pay pharmacy. The 5.5 mg strength is $199. The $149 rate on 2.5 mg and the $199 on 5.5 mg are temporarily reduced prices that run only to 31 December 2026. Because a Foundayo month is 30 days, a full year at the top strength is roughly $3,650 — the cheapest maintenance option of the three.
-
Why is a year more than twelve times the monthly price?
Because on the weekly injections a “month” is 28 days, not a calendar month. Lilly’s terms define a Zepbound month as 28 days and one pen or four vials, and a Wegovy pen box holds four weekly doses. Refilling every 28 days means about 13 fills in a year rather than 12, which adds roughly $450 a year at Zepbound’s $449 rate. The tablets are billed in 30-day months, so for those a year genuinely is about twelve.
-
Do I still need a prescription to buy direct?
Yes. Both manufacturer pharmacies dispense against a prescription from a licensed prescriber; neither prescribes. Buying direct removes the platform fee, not the clinical requirement.
Sources and method
- Wegovy self-pay pricing. NovoCare Pharmacy — Wegovy savings, self pay, and home delivery, and the Wegovy self-pay price guide. Read 5 September 2026.
- Zepbound self-pay pricing and refill terms. LillyDirect — Zepbound, and the Self Pay Journey Program full terms and conditions, which is where the 45-day refill condition and the higher out-of-window prices are stated. Read 5 September 2026.
- Foundayo self-pay pricing. LillyDirect — Foundayo, including the terms defining a month as 30 days and the dated reductions on the 2.5 mg and 5.5 mg strengths. Read 5 September 2026.
- Telehealth comparison. Ro’s published membership and medication pricing, as recorded on our provider comparison, read 25 August 2026.
- Method and limits. Every price here is the manufacturer’s own published self-pay figure, not a third-party or affiliate quote — several aggregator sites currently list ranges for Wegovy that disagree with Novo Nordisk’s own page by a factor of three. Annual totals are the price per fill multiplied by the number of fills a year that each manufacturer’s own definition of a month produces — 28 days for the weekly injections, 30 for the tablets — rather than by a flat twelve, which understates every injection. A real first year costs less because titration starts lower. We have not verified whether any of these pharmacies applies additional shipping or dispensing fees at checkout, nor the eligibility conditions on the insured and Medicare routes each manufacturer advertises.
What licensed providers charge → GLP-1 medications explained → How we source and verify →
Prices verified 5 September 2026. Manufacturer self-pay pricing changes frequently and carries dated offers; we recheck this page quarterly and after any announced change. The next dated change is 31 December 2026, when the Wegovy pen introductory rate and the reduced Foundayo strengths both end.